Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PSNL
stocks logo

PSNL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
17.48M
+4.07%
-0.292
+26.81%
18.47M
-10.38%
-0.270
+50%
18.70M
+8.7%
-0.253
+9.78%
Estimates Revision
The market is revising Downward the revenue expectations for Personalis, Inc. (PSNL) for FY2025, with the revenue forecasts being adjusted by -4.44% over the past three months. During the same period, the stock price has changed by 100.00%.
Revenue Estimates for FY2025
Revise Downward
down Image
-4.44%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-2.85%
In Past 3 Month
Stock Price
Go Up
up Image
+100.00%
In Past 3 Month
Wall Street analysts forecast PSNL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PSNL is 10.60 USD with a low forecast of 9.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast PSNL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PSNL is 10.60 USD with a low forecast of 9.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 10.480
sliders
Low
9.00
Averages
10.60
High
12.00
Current: 10.480
sliders
Low
9.00
Averages
10.60
High
12.00
Morgan Stanley
Equal Weight
maintain
$5 -> $9
2025-11-11
Reason
Morgan Stanley
Price Target
$5 -> $9
2025-11-11
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Personalis to $9 from $5 and keeps an Equal Weight rating on the shares after the company announced Medicare coverage of its ultrasensitive NeXT Personal test for surveillance of cancer recurrence in breast cancer patients.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$10 -> $13
2025-11-11
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$10 -> $13
2025-11-11
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Personalis to $13 from $10 and keeps a Buy rating on the shares after the company received Medicare reimbursement for post-treatment monitoring for cancer recurrence in patients with stage II and III breast cancer. Encouragingly, the reimbursement is effective retroactively starting October 7, at a rate of $3,878 for the initial test and $1,158 for follow-up tests, the analyst tells investors in a research note.
Guggenheim
Subbu Nambi
Buy
maintain
$6 -> $12
2025-11-11
Reason
Guggenheim
Subbu Nambi
Price Target
$6 -> $12
2025-11-11
maintain
Buy
Reason
Guggenheim analyst Subbu Nambi raised the firm's price target on Personalis to $12 from $6 and keeps a Buy rating on the shares after the company announced Medicare coverage for NeXT Personal in breast cancer. This first covered indication keeps Personalis on track for their goal of two indications by year end, notes the analyst, who views this as "a major win for the story" that derisks the clinical revenue outlook for 2025.
H.C. Wainwright
Buy
maintain
$10
2025-11-06
Reason
H.C. Wainwright
Price Target
$10
2025-11-06
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Personalis to $10 from $8.50 and keeps a Buy rating on the shares following the Q3 report. Management continues to expect reimbursement approval for two indications before 2026 and states that the demand for NeXT Personal and clinical trial sample testing continues to grow, the analyst tells investors in a research note.
Lake Street
Thomas Flaten
Buy
maintain
$9 -> $11
2025-11-05
Reason
Lake Street
Thomas Flaten
Price Target
$9 -> $11
2025-11-05
maintain
Buy
Reason
Lake Street analyst Thomas Flaten raised the firm's price target on Personalis to $11 from $9 and keeps a Buy rating on the shares after the company reported Q3 revenue ahead of the guided range, the firm's estimate and consensus. While noting that Personalis lowered 2025 revenue guidance to reflect macro headwinds in the biopharma business, the firm argues that the key driver of future revenue growth and share price appreciation will be reimbursement.
H.C. Wainwright
Swayampakula Ramakanth
Buy
downgrade
$9
2025-08-06
Reason
H.C. Wainwright
Swayampakula Ramakanth
Price Target
$9
2025-08-06
downgrade
Buy
Reason
H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm's price target on Personalis to $8.50 from $9 and keeps a Buy rating on the shares post the Q2 report. The firm says the biopharma translational research delays lead to the lower guidance.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Personalis Inc (PSNL.O) is -9.96, compared to its 5-year average forward P/E of -5.19. For a more detailed relative valuation and DCF analysis to assess Personalis Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.19
Current PE
-9.96
Overvalued PE
0.82
Undervalued PE
-11.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.87
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.16
Undervalued EV/EBITDA
-9.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.53
Current PS
0.00
Overvalued PS
10.54
Undervalued PS
0.52
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 19169.64% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 19169.64% over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

PSNL News & Events

Events Timeline

(ET)
2025-12-01
16:40:00
Morgan Stanley Initiates Coverage on Personalis with Equal Weight Rating, Price Target Raised to $11
select
2025-11-10 (ET)
2025-11-10
09:10:03
Personalis Reveals Medicare Coverage for NeXT Personal Test
select
2025-11-04 (ET)
2025-11-04
16:02:29
Personalis Announces Q3 EPS of 24 Cents, Below Consensus Estimate of 27 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
11-12Benzinga
Morgan Stanley Keeps Equal-Weight Rating on Personalis and Increases Price Target to $9

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing collaboration and information sharing.

  • Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.

[object Object]
Preview
6.0
11-11Benzinga
BTIG Reaffirms Buy Rating on Personalis, Increases Price Target to $12

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: The platform is designed to help traders win in the markets every day with accurate stock market intelligence.

[object Object]
Preview
8.0
11-10Yahoo Finance
Personalis Secures Medicare Approval for Breast Cancer Recurrence Test; Stock Prices Surge

  • Medicare Coverage Announcement: Personalis (PSNL) announced that it has obtained Medicare coverage for its NeXT Personal test, which is used for surveillance purposes.

  • Significance of Coverage: This coverage is expected to enhance access to the NeXT Personal test for patients, potentially improving patient outcomes in monitoring health conditions.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Personalis Inc (PSNL) stock price today?

The current price of PSNL is 10.48 USD — it has increased 3.05 % in the last trading day.

arrow icon

What is Personalis Inc (PSNL)'s business?

Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.

arrow icon

What is the price predicton of PSNL Stock?

Wall Street analysts forecast PSNL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PSNL is 10.60 USD with a low forecast of 9.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Personalis Inc (PSNL)'s revenue for the last quarter?

Personalis Inc revenue for the last quarter amounts to 14.50M USD, decreased -43.62 % YoY.

arrow icon

What is Personalis Inc (PSNL)'s earnings per share (EPS) for the last quarter?

Personalis Inc. EPS for the last quarter amounts to -0.24 USD, decreased -62.50 % YoY.

arrow icon

What changes have occurred in the market's expectations for Personalis Inc (PSNL)'s fundamentals?

The market is revising Downward the revenue expectations for Personalis, Inc. (PSNL) for FY2025, with the revenue forecasts being adjusted by -4.44% over the past three months. During the same period, the stock price has changed by 100.00%.
arrow icon

How many employees does Personalis Inc (PSNL). have?

Personalis Inc (PSNL) has 229 emplpoyees as of December 05 2025.

arrow icon

What is Personalis Inc (PSNL) market cap?

Today PSNL has the market capitalization of 930.67M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free